Dr. Reddy's Laboratories (RDY) PT Raised to $40 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Price: $14.17 +0.43%
Rating Summary:
8 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 8
Rating Summary:
8 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 8
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Dr. Reddy's Laboratories (NYSE: RDY) to $40.00 (from $39.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- ICICI Securities Upgrades KFin Technologies Ltd (KFINTECH:IN) to Add (2)
- Howmet Aerospace Inc. (HWM) PT Lowered to $350 at Jefferies
- Bloomage Biotechnology Corp (688363:CH) PT Lowered to RMB21 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
